Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | GPR88 | Q9GZN0 | 8/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21591851 | 0.85 | ACACB (0.46) | ACACBSMN1; SMN2GPR88TAS1R3TAS1R1 | |
| SCHEMBL863445 | 0.83 | UTS2R (0.45) | ACACBSMN1; SMN2FAAHGPR88UTS2R | |
| SCHEMBL863629 | 0.82 | ACACB (0.45) | ACACBSMN1; SMN2FAAH | |
| SCHEMBL864421 | 0.80 | FAAH (0.51) | ACACBSMN1; SMN2FAAHGPR88ACACA | |
| SCHEMBL864058 | 0.79 | USP9X (0.48) | SMN1; SMN2 | |
| SCHEMBL864059 | 0.79 | USP9X (0.48) | SMN1; SMN2 | |
| SCHEMBL864164 | 0.79 | USP9X (0.50) | ACACBGPR88 | |
| SCHEMBL864278 | 0.78 | SMN1; SMN2 (0.41) | ACACBSMN1; SMN2FAAHGPR88 | |
| SCHEMBL864381 | 0.77 | USP9X (0.60) | ACACBSMN1; SMN2GPR88 | |
| SCHEMBL10125025 | 0.74 | ACACB (0.37) | ACACBSMN1; SMN2FAAHGPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619184-B1 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2018-05-23 | — | — | EP | disclosed |
| EP-2619184-B1 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UNIV MICHIGAN (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UNIV MICHIGAN (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UNIV MICHIGAN (US) | 2014-12-04 | — | — | US | disclosed |
| US-8809377-B2 | Deubiquitinase inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809377-B2 | Deubiquitinase inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809377-B2 | Deubiquitinase inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2619184-A2 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | The Regents of the University of Michigan (US) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012040527-A2 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2012040527-A2 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UCHL1, USP2, USP1 | ACACB 1534/4885SMN1; SMN2 203/4885FAAH 537/4885 |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UCHL1, USP2, USP1 | ACACB 1534/4885SMN1; SMN2 203/4885FAAH 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.